Afficher la notice abrégée

dc.creatorGoldknopf, I. L.en
dc.creatorBryson, J. K.en
dc.creatorStrelets, I.en
dc.creatorQuintero, S.en
dc.creatorSheta, E. A.en
dc.creatorMosqueda, M.en
dc.creatorPark, H. R.en
dc.creatorAppel, S. H.en
dc.creatorShill, H.en
dc.creatorSabbagh, M.en
dc.creatorChase, B.en
dc.creatorKaldjian, E.en
dc.creatorMarkopoulou, K.en
dc.date.accessioned2015-11-23T10:28:34Z
dc.date.available2015-11-23T10:28:34Z
dc.date.issued2009
dc.identifier10.1016/j.bbrc.2009.08.150
dc.identifier.issn0006-291X
dc.identifier.urihttp://hdl.handle.net/11615/28024
dc.description.abstractBlood serum was used to identify protein biomarkers for diagnosis of Parkinson's disease (PD) using analytically validated quantitative 2D-gel electrophoresis, and single variable and multivariate statistics. Using banked samples from a first medical center, we identified 57 specific protein spot biomarkers with disease-specific abnormal levels in serum of patients with PD, Alzheimer's disease, amyotrophic lateral sclerosis and similar neurodegenerative conditions (337 samples), when compared to age-matched normal controls (132 samples). To further assess their clinical usefulness in Parkinson's disease, we obtained prospective newly drawn blood serum samples from a second (56 PD, 30 controls) and third (6 PD, 48 controls) medical center. The protein concentrations of the 57 biomarkers were assessed by 2D-gel electrophoresis. Stepwise linear discriminant analysis selected a combination of 21 of the 57 as optimal to distinguish PD patients from controls. When applied to the samples from the second site, the 21 proteins had sensitivity of 93.3% (52 of 56 PD correctly classified), specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild, 28 of 30 with moderate to severe symptoms, and all of the 6 PD patients from the third site were correctly classified. Eleven of the 21 proteins showed statistically significant abnormal concentrations in patients with mild symptoms, and 14 in patients with moderate-severe symptoms. The protein identities reflect the heterogeneity of Parkinson's disease, and thus may provide the capability of monitoring the blood for a diverse range of PD pathophysiological mechanisms: cellular degeneration, oxidative stress, inflammation, and transport. (C) 2009 Elsevier Inc. All rights reserved.en
dc.sourceBiochemical and Biophysical Research Communicationsen
dc.source.uri<Go to ISI>://WOS:000270764400022
dc.subjectParkinson'sen
dc.subjectNeurodegenerativeen
dc.subjectSerumen
dc.subjectProteinsen
dc.subjectBiomarkersen
dc.subjectDiagnosisen
dc.subjectRESOLUTION 2-DIMENSIONAL ELECTROPHORESISen
dc.subjectALZHEIMERS-DISEASEen
dc.subjectALPHA-SYNUCLEINen
dc.subjectGEL ELECTROPHORESISen
dc.subjectPLASMA PROTEINSen
dc.subjectMESSENGER-RNAen
dc.subjectRAT-LIVERen
dc.subjectMUTATIONSen
dc.subjectGENEen
dc.subjectBIOMARKERSen
dc.subjectBiochemistry & Molecular Biologyen
dc.subjectBiophysicsen
dc.titleAbnormal serum concentrations of proteins in Parkinson's diseaseen
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée